New findings from the Cleveland Clinic suggest that GLP-1 medications, commonly used for managing Type 2 diabetes and promoting weight loss, may also play a role in reducing cancer progression. Dr. Mark Orland, who is affiliated with the Taussig Cancer Institute, led a study involving 12,112 patients with Stage 1 to 3 cancers linked to obesity. The research indicates that patients using GLP-1 drugs exhibited a 33% lower risk of death compared to those on DPP-4 inhibitors, a class of diabetes medications. Notably, patients on GLP-1s showed reduced metastatic progression in six of seven studied cancer types, including non-small cell lung cancer, breast cancer, and liver cancer. For instance, only 10% of patients on GLP-1s progressed to stage IV non-small cell lung cancer, compared to 22% of those on DPP-4s. However, the study's observational nature means that it does not definitively prove that GLP-1s directly affect cancer progression. Orland cautioned that these drugs should not be used for cancer prevention and that further research is essential to validate these findings. The results will be presented at the 2026 American Society of Clinical Oncology annual meeting, highlighting the potential of GLP-1s beyond their current applications.